UBS Group’s Biotech Acquisition Company Unit BIOTU Stock Holding History

UBS Group’s Portfolio BIOTU Stock Details BIOTU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-210	Closed	-$2.11K	–	11433
2022 Q4	$2.11K	Hold	210	–	–	﹤0.01%	9733
2022 Q3	$2K	Hold	210	–	–	﹤0.01%	9876
2022 Q2	$2K	Sell	210 -465	-69%	-$4.6K	﹤0.01%	9739
2022 Q1	$7K	Buy	675 +187	+38%	+$1.87K	﹤0.01%	8909
2021 Q4	$5K	Sell	488 -80	-14%	-$810	﹤0.01%	9461
2021 Q3	$6K	Sell	568 -1,255	-69%	-$12.6K	﹤0.01%	8489
2021 Q2	$18K	Sell	1,823 -588	-24%	-$5.89K	﹤0.01%	7471
2021 Q1	$24K	Buy	+2,411	New	+$24.8K	﹤0.01%	7221

UBS Group's BIOTU Position: Q1 2023 in Review

UBS Group sold out of Biotech Acquisition Company Unit (BIOTU) in Q1 2023, closing a stake of 210 shares — an estimated $2.11K sold.

UBS Group first reported a position in BIOTU in Q1 2021 and held it in 8 quarters. The position peaked at $24K in Q1 2021. 0 funds tracked by Wall St. Rank hold BIOTU as of Q1 2023.

UBS Group reported no remaining Biotech Acquisition Company Unit position as of Q1 2023 after selling out during the quarter.
UBS Group sold 210 Biotech Acquisition Company Unit shares in Q1 2023, an estimated $2.11K.
UBS Group first reported a position in Biotech Acquisition Company Unit in Q1 2021 and held it in 8 quarters.
UBS Group's Biotech Acquisition Company Unit position peaked at $24K in Q1 2021.
0 funds tracked by Wall St. Rank held Biotech Acquisition Company Unit as of Q1 2023.

Based on UBS Group's 13F filing for Q1 2023, filed 12 May 2023.